Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis

Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis

Zoledronic acid, a bisphosphonate, has been approved for treatment and prevention of osteoporosis. This case describes a 73-year-old woman with primary osteoporosis who developed transient hepatotoxicity after zoledronic acid (ZOL) treatment. Three days after ZOL infusion, aspartate aminotransferase...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EXCLI journal 2013-02, Vol.12, p.115-117
Hauptverfasser: Lu, Yanhui, Pei, Yu, Shao, Yinghong, Yan, Shuangtong, Ma, Lichao, Fang, Fusheng, Jin, Mengmeng, Liu, Minyan, Li, Jian, Li, Chunlin
Format: Artikel
Sprache:eng
Schlagworte:
Case Report
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 117
container_issue
container_start_page 115
container_title EXCLI journal
container_volume 12
creator Lu, Yanhui
Pei, Yu
Shao, Yinghong
Yan, Shuangtong
Ma, Lichao
Fang, Fusheng
Jin, Mengmeng
Liu, Minyan
Li, Jian
Li, Chunlin
description Zoledronic acid, a bisphosphonate, has been approved for treatment and prevention of osteoporosis. This case describes a 73-year-old woman with primary osteoporosis who developed transient hepatotoxicity after zoledronic acid (ZOL) treatment. Three days after ZOL infusion, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) were increased by 9.9, 8.1, and 3.7 times, respectively, compared with pretreatment values. Liver protective agents were administered. The aminotransferase returned within normal ranges 12 days post-infusion. Currently, the relationship of ZOL and liver damage is not quite clear, which cannot be explained by its pharmacokinetics. The aim of this case report is to increase the clinician's awareness of the possible adverse effect on the liver, and ZOL should be cautiously administered in patients with liver disease.
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4803018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>27034632</sourcerecordid><originalsourceid>FETCH-LOGICAL-p233t-f38ecd213530b09e450b3e211670fb650366e435fa8dd7f70e5d7d41fc5d6f253</originalsourceid><addsrcrecordid>eNpVkF1LwzAUhoMobk7_guQPFE5ymqTeCDLUCQNv5nVJ87FF2qa0mbP-egtOmXDgvPBwHg7vGZkzyVjGmZDnJ3lGrobhHUAUINQlmXEFmEvkc7JZuU6nmOJnMCGNNLR2b5yl1Ui_Yu1sH9tgqDbBTojqabYTPcRmioeQdrTrQ6P7kcYhudjFPg5huCYXXteDuznuBXl7etwsV9n69fll-bDOOo6YMo-FM5YzFAgV3LlcQIWOMyYV-EoKQCldjsLrwlrlFThhlc2ZN8JKzwUuyP2Pt9tXjbPGtanXdXl8qYw6lP9JG3blNn6UeQEIrJgEt6eCv8vffvAbjPxlHg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Lu, Yanhui ; Pei, Yu ; Shao, Yinghong ; Yan, Shuangtong ; Ma, Lichao ; Fang, Fusheng ; Jin, Mengmeng ; Liu, Minyan ; Li, Jian ; Li, Chunlin</creator><creatorcontrib>Lu, Yanhui ; Pei, Yu ; Shao, Yinghong ; Yan, Shuangtong ; Ma, Lichao ; Fang, Fusheng ; Jin, Mengmeng ; Liu, Minyan ; Li, Jian ; Li, Chunlin</creatorcontrib><description>Zoledronic acid, a bisphosphonate, has been approved for treatment and prevention of osteoporosis. This case describes a 73-year-old woman with primary osteoporosis who developed transient hepatotoxicity after zoledronic acid (ZOL) treatment. Three days after ZOL infusion, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) were increased by 9.9, 8.1, and 3.7 times, respectively, compared with pretreatment values. Liver protective agents were administered. The aminotransferase returned within normal ranges 12 days post-infusion. Currently, the relationship of ZOL and liver damage is not quite clear, which cannot be explained by its pharmacokinetics. The aim of this case report is to increase the clinician's awareness of the possible adverse effect on the liver, and ZOL should be cautiously administered in patients with liver disease.</description><identifier>ISSN: 1611-2156</identifier><identifier>EISSN: 1611-2156</identifier><identifier>PMID: 27034632</identifier><language>eng</language><publisher>Germany: Leibniz Research Centre for Working Environment and Human Factors</publisher><subject>Case Report</subject><ispartof>EXCLI journal, 2013-02, Vol.12, p.115-117</ispartof><rights>Copyright © 2013 Lu et al. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803018/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803018/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,887,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27034632$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Yanhui</creatorcontrib><creatorcontrib>Pei, Yu</creatorcontrib><creatorcontrib>Shao, Yinghong</creatorcontrib><creatorcontrib>Yan, Shuangtong</creatorcontrib><creatorcontrib>Ma, Lichao</creatorcontrib><creatorcontrib>Fang, Fusheng</creatorcontrib><creatorcontrib>Jin, Mengmeng</creatorcontrib><creatorcontrib>Liu, Minyan</creatorcontrib><creatorcontrib>Li, Jian</creatorcontrib><creatorcontrib>Li, Chunlin</creatorcontrib><title>Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis</title><title>EXCLI journal</title><addtitle>EXCLI J</addtitle><description>Zoledronic acid, a bisphosphonate, has been approved for treatment and prevention of osteoporosis. This case describes a 73-year-old woman with primary osteoporosis who developed transient hepatotoxicity after zoledronic acid (ZOL) treatment. Three days after ZOL infusion, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) were increased by 9.9, 8.1, and 3.7 times, respectively, compared with pretreatment values. Liver protective agents were administered. The aminotransferase returned within normal ranges 12 days post-infusion. Currently, the relationship of ZOL and liver damage is not quite clear, which cannot be explained by its pharmacokinetics. The aim of this case report is to increase the clinician's awareness of the possible adverse effect on the liver, and ZOL should be cautiously administered in patients with liver disease.</description><subject>Case Report</subject><issn>1611-2156</issn><issn>1611-2156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpVkF1LwzAUhoMobk7_guQPFE5ymqTeCDLUCQNv5nVJ87FF2qa0mbP-egtOmXDgvPBwHg7vGZkzyVjGmZDnJ3lGrobhHUAUINQlmXEFmEvkc7JZuU6nmOJnMCGNNLR2b5yl1Ui_Yu1sH9tgqDbBTojqabYTPcRmioeQdrTrQ6P7kcYhudjFPg5huCYXXteDuznuBXl7etwsV9n69fll-bDOOo6YMo-FM5YzFAgV3LlcQIWOMyYV-EoKQCldjsLrwlrlFThhlc2ZN8JKzwUuyP2Pt9tXjbPGtanXdXl8qYw6lP9JG3blNn6UeQEIrJgEt6eCv8vffvAbjPxlHg</recordid><startdate>20130213</startdate><enddate>20130213</enddate><creator>Lu, Yanhui</creator><creator>Pei, Yu</creator><creator>Shao, Yinghong</creator><creator>Yan, Shuangtong</creator><creator>Ma, Lichao</creator><creator>Fang, Fusheng</creator><creator>Jin, Mengmeng</creator><creator>Liu, Minyan</creator><creator>Li, Jian</creator><creator>Li, Chunlin</creator><general>Leibniz Research Centre for Working Environment and Human Factors</general><scope>NPM</scope><scope>5PM</scope></search><sort><creationdate>20130213</creationdate><title>Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis</title><author>Lu, Yanhui ; Pei, Yu ; Shao, Yinghong ; Yan, Shuangtong ; Ma, Lichao ; Fang, Fusheng ; Jin, Mengmeng ; Liu, Minyan ; Li, Jian ; Li, Chunlin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p233t-f38ecd213530b09e450b3e211670fb650366e435fa8dd7f70e5d7d41fc5d6f253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Case Report</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Yanhui</creatorcontrib><creatorcontrib>Pei, Yu</creatorcontrib><creatorcontrib>Shao, Yinghong</creatorcontrib><creatorcontrib>Yan, Shuangtong</creatorcontrib><creatorcontrib>Ma, Lichao</creatorcontrib><creatorcontrib>Fang, Fusheng</creatorcontrib><creatorcontrib>Jin, Mengmeng</creatorcontrib><creatorcontrib>Liu, Minyan</creatorcontrib><creatorcontrib>Li, Jian</creatorcontrib><creatorcontrib>Li, Chunlin</creatorcontrib><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>EXCLI journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Yanhui</au><au>Pei, Yu</au><au>Shao, Yinghong</au><au>Yan, Shuangtong</au><au>Ma, Lichao</au><au>Fang, Fusheng</au><au>Jin, Mengmeng</au><au>Liu, Minyan</au><au>Li, Jian</au><au>Li, Chunlin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis</atitle><jtitle>EXCLI journal</jtitle><addtitle>EXCLI J</addtitle><date>2013-02-13</date><risdate>2013</risdate><volume>12</volume><spage>115</spage><epage>117</epage><pages>115-117</pages><issn>1611-2156</issn><eissn>1611-2156</eissn><abstract>Zoledronic acid, a bisphosphonate, has been approved for treatment and prevention of osteoporosis. This case describes a 73-year-old woman with primary osteoporosis who developed transient hepatotoxicity after zoledronic acid (ZOL) treatment. Three days after ZOL infusion, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) were increased by 9.9, 8.1, and 3.7 times, respectively, compared with pretreatment values. Liver protective agents were administered. The aminotransferase returned within normal ranges 12 days post-infusion. Currently, the relationship of ZOL and liver damage is not quite clear, which cannot be explained by its pharmacokinetics. The aim of this case report is to increase the clinician's awareness of the possible adverse effect on the liver, and ZOL should be cautiously administered in patients with liver disease.</abstract><cop>Germany</cop><pub>Leibniz Research Centre for Working Environment and Human Factors</pub><pmid>27034632</pmid><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1611-2156
ispartof EXCLI journal, 2013-02, Vol.12, p.115-117
issn 1611-2156
1611-2156
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4803018
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central
subjects Case Report
title Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T14%3A54%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatotoxicity%20induced%20by%20zoledronic%20acid%20in%20an%20aged%20woman%20with%20primary%20osteoporosis&rft.jtitle=EXCLI%20journal&rft.au=Lu,%20Yanhui&rft.date=2013-02-13&rft.volume=12&rft.spage=115&rft.epage=117&rft.pages=115-117&rft.issn=1611-2156&rft.eissn=1611-2156&rft_id=info:doi/&rft_dat=%3Cpubmed%3E27034632%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27034632&rfr_iscdi=true